MA37777B1 - Préparation pharmaceutique - Google Patents

Préparation pharmaceutique

Info

Publication number
MA37777B1
MA37777B1 MA37777A MA37777A MA37777B1 MA 37777 B1 MA37777 B1 MA 37777B1 MA 37777 A MA37777 A MA 37777A MA 37777 A MA37777 A MA 37777A MA 37777 B1 MA37777 B1 MA 37777B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical preparation
antibody
high concentration
present
viscosity
Prior art date
Application number
MA37777A
Other languages
English (en)
Other versions
MA20150436A1 (fr
Inventor
Andrew Jeffrey Yates
James Gregory Clipstone
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48745904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37777(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of MA20150436A1 publication Critical patent/MA20150436A1/fr
Publication of MA37777B1 publication Critical patent/MA37777B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des procédés et des moyens permettant de réduire la viscosité d'une préparation pharmaceutique comprenant un anticorps ou une autre protéine thérapeutique à une concentration élevée. La présente invention concerne une préparation pharmaceutique liquide qui comprend un anticorps à une concentration élevée et présente une viscosité réduite n'empêchant pas le traitement ou l'injection de ladite préparation pharmaceutique.
MA37777A 2012-06-21 2013-06-20 Préparation pharmaceutique MA37777B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261662621P 2012-06-21 2012-06-21
PCT/EP2013/062898 WO2013190047A1 (fr) 2012-06-21 2013-06-20 Préparation pharmaceutique

Publications (2)

Publication Number Publication Date
MA20150436A1 MA20150436A1 (fr) 2015-11-30
MA37777B1 true MA37777B1 (fr) 2017-07-31

Family

ID=48745904

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37777A MA37777B1 (fr) 2012-06-21 2013-06-20 Préparation pharmaceutique

Country Status (25)

Country Link
US (1) US20150150979A1 (fr)
EP (1) EP2864356A1 (fr)
JP (1) JP6157611B2 (fr)
KR (1) KR20150032941A (fr)
CN (1) CN104520326A (fr)
AR (1) AR091530A1 (fr)
AU (1) AU2013279347A1 (fr)
BR (1) BR112014031841A2 (fr)
CA (1) CA2876012A1 (fr)
CL (1) CL2014003283A1 (fr)
CO (1) CO7170174A2 (fr)
EA (1) EA201590061A1 (fr)
EC (1) ECSP15002095A (fr)
HK (1) HK1205146A1 (fr)
IL (1) IL235921A0 (fr)
MA (1) MA37777B1 (fr)
MX (1) MX2014014717A (fr)
NZ (1) NZ702342A (fr)
PE (1) PE20150190A1 (fr)
PH (1) PH12014502596A1 (fr)
SG (1) SG11201407779YA (fr)
TN (1) TN2014000498A1 (fr)
TW (1) TW201406398A (fr)
WO (1) WO2013190047A1 (fr)
ZA (1) ZA201409020B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110496099B (zh) 2013-09-11 2022-06-21 伊戈尔生物药品股份有限公司 包含粘度降低剂的液体蛋白质制剂
MX2017004306A (es) 2014-10-01 2017-12-20 Eagle Biologics Inc Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad.
CN109496153B (zh) 2016-05-28 2024-04-23 印度政府生物技术部独立机构拉吉夫甘地生物技术中心 作为肝细胞癌治疗剂的龙葵皂苷b及其衍生物
CA3040342A1 (fr) * 2016-10-31 2018-05-03 Fresenius Kabi Deutschland Gmbh Composition pharmaceutique liquide
JP7177777B2 (ja) 2017-01-11 2022-11-24 セルトリオン， インク． 安定した液体製剤
WO2018211517A1 (fr) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. Formulations de protéines à haute concentration ayant une viscosité réduite
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
WO2022109052A1 (fr) * 2020-11-18 2022-05-27 Bexson Biomedical, Inc. Formulations de flumazénil pour injection sous-cutanée et méthodes de traitement utilisant des modulateurs du récepteur gaba

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030463A2 (fr) * 2000-10-12 2002-04-18 Genentech, Inc. Formulations de proteine concentrees a viscosite reduite
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
EP1610820B2 (fr) * 2003-04-04 2013-08-21 Genentech, Inc. Preparations d'anticorps et de proteines a forte concentration
WO2006096490A2 (fr) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Compositions d'anticorps anti-madcam
CN101600457B (zh) * 2007-01-09 2014-01-08 惠氏公司 抗il-13抗体调配物和其用途
DK2170390T3 (en) * 2007-06-14 2019-01-21 Biogen Ma Inc NATALIZUMABANTISTIC FORMULATIONS
MX2012012743A (es) * 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
SG10201912670XA (en) * 2010-05-14 2020-02-27 Amgen Inc High concentration antibody formulations
US8754195B2 (en) * 2010-07-02 2014-06-17 Medimmune, Llc Antibody formulations
JP2014510152A (ja) * 2011-04-07 2014-04-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 粘度が低減された処方物
JP6024025B2 (ja) * 2011-05-02 2016-11-09 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 少容量投与用のアロタイプ選択抗体の限外濾過濃縮

Also Published As

Publication number Publication date
ECSP15002095A (es) 2015-11-30
CN104520326A (zh) 2015-04-15
CA2876012A1 (fr) 2013-12-27
MA20150436A1 (fr) 2015-11-30
EP2864356A1 (fr) 2015-04-29
BR112014031841A2 (pt) 2017-06-27
MX2014014717A (es) 2015-03-06
KR20150032941A (ko) 2015-03-31
AU2013279347A1 (en) 2014-12-18
WO2013190047A1 (fr) 2013-12-27
NZ702342A (en) 2016-07-29
ZA201409020B (en) 2016-09-28
JP2015520206A (ja) 2015-07-16
US20150150979A1 (en) 2015-06-04
CO7170174A2 (es) 2015-01-28
PE20150190A1 (es) 2015-02-13
SG11201407779YA (en) 2015-02-27
IL235921A0 (en) 2015-01-29
AR091530A1 (es) 2015-02-11
PH12014502596A1 (en) 2015-01-12
CL2014003283A1 (es) 2016-04-01
TN2014000498A1 (en) 2016-03-30
TW201406398A (zh) 2014-02-16
EA201590061A1 (ru) 2015-05-29
HK1205146A1 (en) 2015-12-11
JP6157611B2 (ja) 2017-07-05

Similar Documents

Publication Publication Date Title
MA20150436A1 (fr) Préparation pharmaceutique
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
Boczek et al. The role of G protein-coupled receptors (GPCRs) and calcium signaling in schizophrenia. Focus on GPCRs activated by neurotransmitters and chemokines
MA44659B1 (fr) Anticorps anti-tim-3 et compositions
MA41932B1 (fr) Méthodes de traitement ou de prévention de migraines
MX2012010418A (es) Inhibidores syk de imidazopiridinas.
MA40041A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
ATE516814T1 (de) 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
BR112015025711A8 (pt) uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer
BR112013008140A2 (pt) "compostos imidazotriazinona".
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
MA38986A3 (fr) Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
EA200970374A1 (ru) Лечение антиаритмическими средствами и омега-3 жирными кислотами и их комбинированным продуктом
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA43113A (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
BR112017014793A2 (pt) regime de dosagem para antagonistas de madcam
MA39342B2 (fr) Anticorps il -21
MA38190A2 (fr) Inhibiteurs d'autotaxine
MA35165B1 (fr) Induction de tolérance immune par utilisation de méthotrexate
FR3061021B1 (fr) Antagoniste specifique de tlr4 dans le traitement du myelome multiple
MA35927B1 (fr) Polythérapie pour le traitement d'un cancer de l'ovaire